| Value | ₹0.01 Cr |
|---|
NSE filing, NSE: MAXESTATES. Summary written from the filing by ALFA Finder's alert engine.
Max Estates Ltd: key numbers
- Share price
- ₹513.75
- Market cap
- ₹8,404 Cr
- Revenue (annual)
- ₹199.4 Cr
- Net profit (annual)
- ₹12.51 Cr
- P/E (TTM)
- 726.8×Sector 35.9×
- Promoter holding
- 45.23%-0.03% QoQ
- FII holding
- 26.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Max Estates Ltd
All →Max Estates Investor Presentation: Key Takeaways
Q2 FY27 pre-sales ₹2,092 Cr (~14x YoY); H1 FY27 pre-sales ₹3,184 Cr, collections ₹1,051 Cr. Reported P&L is small (FY26 revenue ₹199.4 Cr, PBT ₹23.3 Cr); ₹4,800–5,700 Cr embedded PBT to be recognised FY28–FY31.
Max Estates Results Update
Max Estates reported H1 FY27 pre-sales of INR 3,200 crore and Q2 PAT of INR 4.7 crore. It also signed an MOU for a Delhi land acquisition.
Max Estates Debt & Borrowing: ₹350 Cr
Max Estates' board approved a ₹350 crore corporate guarantee for a wholly-owned subsidiary's term loan. Monitoring agency reports on its QIP and warrant proceeds were also filed.
- Value
- ₹350.0 Cr
Max Estates Q2 FY27 Results: Net Profit ₹4.7 Cr, Down 39.7% YoY
Max Estates Ltd reported revenue from operations of ₹52.8 Cr (+8.2% YoY) and net profit of ₹4.7 Cr (-39.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹4.7 Cr · -39.7% YoY
Max Estates Board Meeting Date
Max Estates Limited has informed exchanges that its board will meet on 4 November 2026 to consider unaudited results for the quarter and half year ended 30 September 2026. The trading window stays closed until 6 November 2026.
Max Estates Employee Stock Options
Max Estates allotted 632 equity shares to an option holder under its ESOP Plan 2023. The allotment raises paid-up capital; no transaction price is stated.
Other merger & restructuring announcements
All →Narayana Hrudayalaya Merger & Restructuring
Narayana Hrudayalaya's NCLT Bengaluru bench sanctioned the demerger of clinical services from its subsidiary NH Integrated Care. Order uploaded today; effectiveness awaits certified copy filings.
Abans Enterprises Merger & Restructuring
Abans Enterprises' board approved voluntary liquidation of wholly owned subsidiary AGJT, subject to shareholder approval. Completion is expected within one year.
- Execution
- Expected within one year, subject to approvals and statutory formalities
Aurobindo Pharma Merger & Restructuring Worth ₹29 Cr
Aurobindo Pharma approved transferring 100% of Auro Pharma LLC, Russia, between wholly owned subsidiaries. Cash consideration is about INR 29 crore, subject to adjustments.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Choice International Merger & Restructuring Worth ₹1.27 Cr
Choice International sold a unit or subsidiary to Arrowbridge Trade for Rs.1.275 Crore in cash. The buyer is unrelated and the deal is at arm's length.
- Value
- ₹1.27 Cr
Shringar House of Mangalsutra Merger & Restructuring Worth ₹5 Cr
Shringar House of Mangalsutra will incorporate a wholly owned jewellery subsidiary, subscribing Rs 5 Crore in cash. The subsidiary becomes a related party once formed.
- Value
- ₹5.00 Cr
HEG Advanced Materials Merger & Restructuring Worth ₹10.12 Cr
HEG Advanced Materials closed LNJ Trading FZCO, its Dubai-based wholly owned subsidiary, as part of overseas structure rationalisation. The filing quantifies the effect at AED 4,048,000.
- Value
- ₹10.12 Cr